WILLIAM WONG to Carcinoma, Hepatocellular
This is a "connection" page, showing publications WILLIAM WONG has written about Carcinoma, Hepatocellular.
Connection Strength
1.845
-
Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection. Liver Int. 2024 Jun; 44(6):1383-1395.
Score: 0.462
-
Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study. CMAJ Open. 2021 Jan-Mar; 9(1):E167-E174.
Score: 0.376
-
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat. 2021 02; 28(2):260-267.
Score: 0.368
-
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. Oncologist. 2020 03; 25(3):e512-e519.
Score: 0.343
-
Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol. 2013 Mar; 27(3):137-47.
Score: 0.215
-
Cost Effectiveness of Hepatocellular Carcinoma Surveillance?After a Sustained Virologic Response to Therapy?in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1840-1849.e16.
Score: 0.081